William D. Waddill

Director William D. Waddill sells 9,000 PTGX shares at $117.94 under pre-arranged 10b5-1 plan; retains 7,825 shares.

Director William D. Waddill sold 9,000 shares at $117.94 on 2026-06-23 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-27, reducing his non-derivative holdings by 53.5% to 7,825 shares. The trade is scheduled rather than discretionary, so it reflects plan mechanics rather than a real-time market judgment. Protagonist Therapeutics has experienced severe turbulence: annual revenue declined 89.4% year-over-year and the company was unprofitable over its most recent full fiscal year, though the latest quarter showed $56.4M revenue and $3.8M net income. The stock has recovered 22.6% over the past 30 days and 23.9% over 90 days, trading at $122.63 (2.9% below its 52-week high of $126.25). Investors should monitor whether further 10b5-1 execution or additional open-market sales emerge, as well as the company's ability to sustain recent profitability amid the prior year's sharp revenue decline.

Director William D. Waddill sold 20,000 shares of PTGX at $83.68, reducing position by 71.9% to 7,825 shares

Director William D. Waddill sold 20,000 shares (20.0K shares) at $83.68 on 2026-02-06, liquidating 71.9% of his holdings and leaving a post-transaction position of 7,825 shares (7.8K shares). The company trades at a P/E of 115.74 with a market cap of $5,281,948,620.34 ($5.3B), while reporting quarterly revenue of $4,712,000.00 ($4.7M) against net income of $-39,339,000.00 ($-39.3M). The substantial reduction in Waddill's stake—divesting nearly three-quarters of his holdings—warrants examination of the company's profitability trajectory and whether the director's decision reflects structural concerns at a firm with outsized valuation relative to current earnings generation.